HIV and Hepatitis.com Coverage of the
XVII International AIDS Conference
(AIDS 2008) August 3 - 8, 2008, Mexico City, Mexico
   HIV and AIDS Main Section       FDA-approved HIV and AIDS Treatments
IAC 2008 (AIDS 2008) CME/CE Podcast Updates

Webcast Coverage from Kaisernetwork
 HIV and AIDS Articles
Depot Formulation of Rilpivirine (TMC278) May Offer Months of Sustained Anti-HIV Activity with a Single Injection
HIV Prevention -- Including PrEP -- a Key Focus of International AIDS Conference
Study Shows Nevirapine (Viramune) Reaches Semen Better than Other NNRTIs or Protease Inhibitors
High HIV Viral Load Is a Risk Factor for Tuberculosis within 3 Months of Starting HAART
Tuberculosis, HAART, and Survival in the THRio Cohort in Rio de Janerio, Brazil
No Increased Risk of Birth Defects with Prenatal Lopinavir/ritonavir (Kaletra) Exposure
Exposure to Antiretroviral Drugs during Pregnancy Does Not Impair HIV Negative Children's Mental Development
New NRTI Apricitabine Demonstrates Good Safety in Early Clinical Trial
Studies Look at Association between CD4 Cell Count and Cardiovascular Risk in People with HIV
Women and Men Respond Similarly to Antiretroviral Drugs and Experience Comparable Side Effects: GRACE, M05-730, CASTLE, ARTEM
Didanosine (Videx-EC) + Emtricitabine (Emtriva) + Atazanavir (Reyataz) Inferior for Initial HIV Treatment: PEARLS Trial
Switching from Other Ritonavir-boosted Protease Inhibitors to Boosted Atazanavir (Reyataz) Did Not Improve Body Fat Accumulation: REAL Study
Sexual Transmission of HIV May Remain a Risk despite Antiretroviral Therapy
Social Stigma Felt by Pregnant HIV Positive Women in the U.S.
Virological Success with Raltegravir (Isentress) plus Etravirine (Intelence) plus Boosted Darunavir (Prezista) in Patients with Multidrug-resistant HIV: TRIO Trial
New NNRTIs IDX899 and RDE806 Appear Safe and Effective in Early Clinical Trials
Pregabalin vs Placebo for the Treatment of Painful HIV-associated Peripheral Neuropathy
Study Presentation Overstates Tenofovir Kidney Toxicity Risk
Protective Effect of Circumcision against HIV Infection Is Sustained for Nearly Two Years
NIAID Director Anthony Fauci Suggests HIV Cure Is Not an Impossible Dream
Are Abacavir/lamivudine (Epzicom) and Tenofovir/emtricitabine (Truvada) Equally Effective as NRTI Backbones? ACTG 5202 and HEAT Disagree
Does Abacavir (Ziagen) Raise Heart Attack Risk? Conflicting Answers from SMART and 54-study Pooled Analysis
What is the Risk of Kidney Toxicity Associated with Tenofovir (Viread)?
Boosted Atazanavir and Lopinavir/ritonavir (Kaletra) Have Similar Efficacy, but Side Effects Differ across Racial/ethnic Groups
Lopinavir/ritonavir (Kaletra) Tablet Dosed Once-Daily or Twice-Daily Confers Similar Clinical Results across Racial/ethnic Lines
A Comparison of the Single-dose Bioavailability of a Ritonavir Tablet Formulation Compared with the Current Soft Gel Capsule
Raltegravir (Isentress) Continues to Demonstrate Viral Load Suppression and Good Tolerability at 96 Weeks in Treatment-naive Patients
Investigational Next-generation NNRTI Rilpivirine (TMC278) Demonstrates Potent Antiviral Activity at 96 Weeks in Treatment-naive Individuals
Growth Hormone Improves Lipodystrophy, but Has Detrimental Effect on Blood Glucose
Men Who Have Sex with Men Remain Disproportionately Affected by HIV/AIDS in the U.S. and Worldwide
International AIDS Society-USA Updates Antiretroviral Treatment Guidelines
New Testing Method Yields Higher Estimate for U.S. HIV Incidence
Attitudes and Perceptions About HIV/AIDS Among HIV Patients
Nevirapine (Viramune) May Be Less Effective When Combined with Tuberculosis Treatment
Antiretroviral Therapy is Effective for Injection Drug Users
HIV/AIDS Epidemic Has Stabilized Worldwide, According to UNAIDS
 HIV-HCV or HIV-HBV Coinfection Articles
Risk of Mother-to-Child HIV and HCV Transmission from Coinfected Pregnant Women
Are HIV Positive People More Likely to Relapse after Completion of Hepatitis C Treatment with Pegylated Interferon plus Ribavirin
Further Evidence of Sexual Transmission of Hepatitis C Virus among HIV Positive Men Who Have Sex with Men
Do HIV-HCV Coinfected Patients Respond Better to Pegasys or PegIntron as Part of Combination Therapy for Chronic Hepatitis C?
HIV-HCV Coinfected Individuals May Have a Higher Risk of Cardiovascular Disease than HIV Positive People without Hepatitis C
Hepatitis C Virus Kinetics during the First 24 Hours of Treatment Predicts Rapid and End-of-treatment Response in HIV-HCV Coinfected Patients
Predictors of Hepatitis B Surface Antigen Loss in HIV-HBV Coinfected Individuals

 

AIDS 2008 PHOTO LIBRARY


 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sign up to receive
our twice-weekly
e-Newsletterr

Google Custom Search
 

HIV-HCV Coinfection
Main Section

HIV-HBV Coinfection
Main Section